Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05024097 · ClinicalTrials.gov registry record · Phase 2
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
A Phase 2 study of Rectal Cancer, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 3
- Study locations
NCT05024097 is a Phase 2 study of Rectal Cancer that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 43 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05024097, a Phase 2 study of Rectal Cancer, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 3
- Study locations
Study Summary
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.
Conditions Studied
Interventions
- DRUG Etrumadenant (AB928)
- RADIATION Radiation therapy
- DRUG FOLFOX regimen
- DRUG Zimberelimab (AB122)
Study Locations (3)
New York
- Weill Cornell Medical College - New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
- New York Presbyterian Hospital - Queens - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05024097
The ClinicalTrials.gov registry entry for NCT05024097 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Etrumadenant (AB928) is the first listed.
NCT05024097 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05024097 about?
NCT05024097 is a clinical study titled "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.". Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combi...
What is the current status of trial NCT05024097?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2022-03-31. Estimated completion is 2030-12.
What conditions does trial NCT05024097 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT05024097?
The interventions under investigation include: Etrumadenant (AB928) (DRUG), Radiation therapy (RADIATION), FOLFOX regimen (DRUG), Zimberelimab (AB122) (DRUG).
Who is sponsoring clinical trial NCT05024097?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05024097 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.